東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Estrogen-induced gene expression and...

Schlumbrecht, Matthew P.

Linked to FindBook

Google Book

Amazon

博客來

Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary./
Author:	Schlumbrecht, Matthew P.
Description:	52 p.
Notes:	Source: Masters Abstracts International, Volume: 48-04, page: 2242.
Contained By:	Masters Abstracts International48-04.
Subject:	Health Sciences, Public Health. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1474726
ISBN:	9781109702446

Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary.
Schlumbrecht, Matthew P.

Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary. - 52 p.

Source: Masters Abstracts International, Volume: 48-04, page: 2242.

Thesis (M.P.H.)--The University of Texas School of Public Health, 2010.

Background. Assessment of estrogen receptor (ER) expression has inconsistent utility as a prognostic marker in epithelial ovarian carcinoma. In breast and endometrial cancers, the use of estrogen-induced gene panels, rather than ER expression alone, has shown improved prognostic capability. Specifically, over-expression of estrogen-induced genes in these tumors is associated with a better prognosis and signifies estrogen sensitivity that can be exploited with hormone antagonizing agents. It was therefore hypothesized that estrogen-induced gene expression in ovarian carcinoma would successfully predict outcomes and differentiate between tumors of varying estrogen sensitivities. Methods. Two hundred nineteen (219) patients with ovarian cancer who underwent surgery at M. D. Anderson between 2004 and 2007 were identified. Of these, eighty-three (83) patients were selected for inclusion because they had advanced stage, high-grade serous carcinoma of the ovary or peritoneum, had not received neoadjuvant chemotherapy, and had readily available frozen tissue for study. All patients had also received adjuvant treatment with platinum and taxane agents. The expression of seven genes known to be induced by estrogen in the female reproductive tract (EIG121, sFRP1, sFRP4, RALDH2, PR, IGF-1, and ER) was measured using qRT-PCR. Unsupervised cluster analyses of multiple gene permutations were used to categorize patients as high or low estrogen-induced gene expressors. QPCR gene expression results were then compared to ER and PR immunohistochemical (IHC) expression. Cox proportional hazards models were used to evaluate the effects of both individual genes and selected gene clusters on patient survival. Results. Median follow-up time was 38.7 months (range 1-68 months). In a multivariate model, overall survival was predicted by sFRP1 expression (HR 1.10 [1.02-1.19], p=0.01) and EIG121 expression (HR 1.28 [1.10-1.49], p<0.01). A cluster defined by EIG121 and ER was further examined because that combination appeared to reasonably segregate tumors into distinct groups of high and low estrogen-induced gene expressors. Shorter overall survival was associated with high estrogen-induced gene expressors (HR 2.84 [1.11-7.30], p=0.03), even after adjustment for race, age, body mass index, and residual disease at debulking. No difference in IHC ER or PR expression was noted between gene clusters. Conclusion. In sharp contrast to breast and endometrial cancers, high estrogen-induced gene expression predicts shorter overall survival in patients with high-grade serous ovarian carcinoma. An estrogen-induced gene biomarker panel may have utility as prognostic indicator and may be useful to guide management with estrogen antagonists in this population.

ISBN: 9781109702446Subjects--Topical Terms:

1017659
Health Sciences, Public Health.

Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary.
LDR:03803nam 2200301 4500 001 1403605
005 20111118100017.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781109702446
035 $a (UMI)AAI1474726
035 $a AAI1474726
040 $a UMI $c UMI
100 1 $a Schlumbrecht, Matthew P. $3 1682880
245 1 0 $a Estrogen-induced gene expression and patient survival in high-grade serous carcinoma of the ovary.
300 $a 52 p.
500 $a Source: Masters Abstracts International, Volume: 48-04, page: 2242.
500 $a Advisers: Sally W. Vernon; Russell R. Broaddus.
502 $a Thesis (M.P.H.)--The University of Texas School of Public Health, 2010.
520 $a Background. Assessment of estrogen receptor (ER) expression has inconsistent utility as a prognostic marker in epithelial ovarian carcinoma. In breast and endometrial cancers, the use of estrogen-induced gene panels, rather than ER expression alone, has shown improved prognostic capability. Specifically, over-expression of estrogen-induced genes in these tumors is associated with a better prognosis and signifies estrogen sensitivity that can be exploited with hormone antagonizing agents. It was therefore hypothesized that estrogen-induced gene expression in ovarian carcinoma would successfully predict outcomes and differentiate between tumors of varying estrogen sensitivities. Methods. Two hundred nineteen (219) patients with ovarian cancer who underwent surgery at M. D. Anderson between 2004 and 2007 were identified. Of these, eighty-three (83) patients were selected for inclusion because they had advanced stage, high-grade serous carcinoma of the ovary or peritoneum, had not received neoadjuvant chemotherapy, and had readily available frozen tissue for study. All patients had also received adjuvant treatment with platinum and taxane agents. The expression of seven genes known to be induced by estrogen in the female reproductive tract (EIG121, sFRP1, sFRP4, RALDH2, PR, IGF-1, and ER) was measured using qRT-PCR. Unsupervised cluster analyses of multiple gene permutations were used to categorize patients as high or low estrogen-induced gene expressors. QPCR gene expression results were then compared to ER and PR immunohistochemical (IHC) expression. Cox proportional hazards models were used to evaluate the effects of both individual genes and selected gene clusters on patient survival. Results. Median follow-up time was 38.7 months (range 1-68 months). In a multivariate model, overall survival was predicted by sFRP1 expression (HR 1.10 [1.02-1.19], p=0.01) and EIG121 expression (HR 1.28 [1.10-1.49], p<0.01). A cluster defined by EIG121 and ER was further examined because that combination appeared to reasonably segregate tumors into distinct groups of high and low estrogen-induced gene expressors. Shorter overall survival was associated with high estrogen-induced gene expressors (HR 2.84 [1.11-7.30], p=0.03), even after adjustment for race, age, body mass index, and residual disease at debulking. No difference in IHC ER or PR expression was noted between gene clusters. Conclusion. In sharp contrast to breast and endometrial cancers, high estrogen-induced gene expression predicts shorter overall survival in patients with high-grade serous ovarian carcinoma. An estrogen-induced gene biomarker panel may have utility as prognostic indicator and may be useful to guide management with estrogen antagonists in this population.
590 $a School code: 0219.
650 4 $a Health Sciences, Public Health. $3 1017659
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0573
690 $a 0992
710 2 $a The University of Texas School of Public Health. $b Epidemiology & Disease Control. $3 1019542
773 0 $t Masters Abstracts International $g 48-04.
790 1 0 $a Vernon, Sally W., $e advisor
790 1 0 $a Broaddus, Russell R., $e advisor
790 1 0 $a Stock, Thomas H. $e committee member
790 $a 0219
791 $a M.P.H.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1474726